2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Clinical Procedures, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Radiation Therapy, Adverse Events, Biological Processes, Apoptosis, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Quality Improvement, Diseases, Infectious Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Measurable Residual Disease, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly
PAPER

3538 Second primary malignancies following frontline treatment for follicular lymphoma: A systematic review and meta-analysis of 8,549 patients

Sarah Kricheff, MD, Ananya Garg, MD2, Alex Eishingdrelo, MD3, Mohammad Alhomoud, MD4, Roni Shouval Jr, MD, PhD5, Kai Rejeski, MD6, Tobias Tix, MD7, Edward R. Scheffer Cliff, MD, MPH8, Ricardo Sanchez Mendez, MD9, Samuel Yamshon, MD10
1 NYU Grossman School of Medicine, New York, New York, United States
2 NYU Grossman School of Medicine, New York, New York, United States
3 NYU Grossman School of Medicine, New York, New York, United States
4 Memorial Sloan Kettering Cancer Center, New York, New York, United States
5 Memorial Sloan Kettering Cancer Center, New York, New York, United States
6 LMU University Hospital, Munich, Germany, Memorial Sloan Kettering Cancer Center, New York, New York, United States
7 LMU University Hospital, Munich, Germany
8 Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia, Walter and Eliza Hall Institute of Medical Research, Melnbourne, VIC, Australia
9 Icahn School of Medicine at Mount Sinai, New York, New York, United States
10 NYU Grossman School of Medicine, New York, New York, United States, NYU Langone Health, New York, New York, United States

Introduction
Follicular lymphoma (FL) is a typically indolent disease with the therapeutic goal of improving survival while minimizing toxicity. Second primary malignancies (SPMs) are important drivers of morbidity and mortality, yet the SPM patterns following first-line (1L) FL treatments are poorly characterized. We performed a systematic review and meta-analysis of 1L FL treatments to quantify overall and subtype-specific SPM rates, compare contemporary frontline treatment classes, and characterize temporal patterns of SPM incidence after treatment.

Methods
Studies investigating 1L treatments in grades 1-3A FL from 2010-2025 were included. Studies with grade 3B FL, SPM outcomes incompletely reported, therapies not included in current NCCN guidelines, or radioimmunotherapy were excluded. Treatment classes included chemotherapy (chemo), single-agent monoclonal antibody (MAB only), and immunomodulator (IMiD) regimens. Cumulative incidence of solid and hematologic (lymphoid and myeloid) SPMs and SPM-related mortality were extracted. Random-effects models pooled SPM incidence by tumor subtype and treatment class. Mixed-effects meta-regression was used to evaluate rates accounting for covariates. SPM incidence was standardized per 100 patient-years (py) to account for differences in follow-up.

Results
29 studies with 40 distinct treatment arms were included comprising 8,549 patients and 49,937 patient-years of follow-up. Pooled cumulative incidence of SPMs was 8.4% with a standardized rate of 1.37 per 100-py. Solid tumors occurred nearly four times as frequently as hematologic malignancies (incidence 7% vs 1.7%, 1.05 vs 0.27 per 100-py) with most hematologic SPMs being myeloid (1.4%, 0.25 per 100-py). Though the incidence of all SPMs with IMiDs was higher than chemo (12.2% vs 7.2%, p = 0.005), rates were not significant after accounting for follow-up (1.65 vs 1.29 SPMs per 100-py, p = 0.37). IMiDs also had a higher incidence of all-grade SPMs relative to MAB-only regimens but did not reach significance (12.2% vs 7.9%, p=0.08). No differences were seen between chemo and MAB-only (7.2% vs 7.9%, p = 0.76). In multivariate meta-regression, no differences in SPM rates were observed when controlling for treatment type, median age, and median follow-up.

For solid SPMs, cumulative incidence was 11.1% for IMiD, 6.6% for chemo, and 3.6% for MAB-only; differences for IMiD vs chemo (p=0.006) and IMiD vs MAB-only (p=0.007) were statistically significant, while chemo vs MAB-only was not (p=0.16). After standardization for follow-up, SPM rates per 100-py were 1.62 for IMiDs, 1.06 for chemo, and 0.46 for MAB-only; differences between IMiD and MAB-only (p<0.001) and chemo and MAB-only (p<0.001) were significant, but between IMiD and chemo were not (0.09). These trends for solid SPMs remained significant after meta-regression controlling for median age and follow-up (ref = MAB only; chemo: p < 0.001; IMiD: p< 0.001). There was no difference in hematologic or myeloid malignancies between treatment groups.

Incidence of SPM-related deaths was 1.5%/0.26 deaths per 100-py. Despite the nearly 4-fold higher incidence of solid SPMs, hematologic SPMs were responsible for a large portion of SPM-related mortality with an incidence of 0.97%/0.18 per 100-py for solid SPMs vs 0.69%/0.13 per 100-py for hematologic SPMs. The majority of deaths from hematologic SPMs were myeloid diseases with an incidence of 0.53%/0.11 per 100-py. There were no differences in SPM-related mortality between treatment types.

Conclusion
Solid SPMs occurred nearly four times more frequently than hematologic SPMs, yet a substantial proportion of SPM-related deaths were attributable to hematologic, particularly myeloid, SPMs. Surprisingly, no differences in the cumulative incidence of SPMs were observed between chemotherapy- and MAB-only regimens. After standardizing for follow-up, IMiD and chemo-based regimens had significantly higher rates of solid SPMs compared to MAB-only regimens. No differences in hematologic SPMs or SPM-related mortality were seen between treatment types, possibly due to insufficient power for these rare events. Across all 1L FL treatment types, SPMs are an important cause of long-term morbidity and mortality. These findings underscore the need to identify predictors of SPM risk and develop surveillance approaches.

Sarah Kricheff, MD: No relevant conflicts of interest to declare.